Logo

Boehringer Ingelheim and Eli Lilly Report the US FDA's Acceptance of sNDA and Granted Priority Review for Jardiance (empagliflozin) to Treat HFpEF

Share this

Boehringer Ingelheim and Eli Lilly Report the US FDA's Acceptance of sNDA and Granted Priority Review for Jardiance (empagliflozin) to Treat HFpEF

Shots:

  • The sNDA is based on P-III EMPEROR-Preserved trial evaluates the safety and efficacy of Jardiance (10mg, qd) vs PBO in 5,988 patients with chronic HFpEF with/out diabetes
  • The results showed a 21% reduction in relative risk for the composite 1EPs of CV death or hospitalization in adults with HF with LVEF The results were presented at ESC 2021 and published in NEJM
  • The therapy has previously received FTD from the US FDA to reduce the risk of CV death and hospitalization for HF & is currently indicated for adults with HFrEF. If Jardiance is approved, it will be the first clinically proven treatment for patients with HF regardless of ejection fraction

Ref: PR Newswire | Image: Boehringer Ingelheim

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions